Octopus Ventures led the seed financing, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, to commercialise live cell imaging technology.
"University spin-outs like CellVoyant are at the heart of the UK’s thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments."
The financing was co-led by Radical Ventures and Temasek to fuel expansion in the United States.
"The next generation of software won’t run on code, it will run on models fueled by training data. We let our clients easily turn human knowledge into AI models, improving the safety and accuracy of AI. This is incredibly powerful, and in the right hands, can literally save lives. If we want to build software that tackles unsolved frontiers in human health, or our climate, this is the only way"
The seed round was led by Amadeus Capital Partners with participation from Partech, Air Street Capital, and Miele Venture.
"The story of the last 5 years for AI-first companies has been one of rapidly evolving tooling and infrastructure best practices. The very best AI-first companies are now moving from their home-grown data annotation, versioning and model lifecycle management tools to V7’s SaaS platform because it abstracts this complexity and exposes industry best practices. Companies can now iterate faster and have confidence in the robustness of their production models by building on V7."
